Skip to content

Alethia™ Pertussis 480750

by Meridian Bioscience Inc.

Ref 480750

Alethia Pertussis 480750 is a bordetella pertussis nucleic acid IVD (EU IVDR Class C; FDA Class II; FDA product code OZZ, Bordetella Pertussis Dna Assay System) made by Meridian Bioscience Inc., registered in EUDAMED on 15 Sep 2026 (Basic UDI-DI 008407331ALETHIACLC011RE) and listed in FDA GUDID since 8 Jan 2019 (UDI-DI 00840733102226), active as of 8 Nov 2026.

Active European Union. Also listed in GUDID (US).

CE IVDR

Valid until

No date given

EUDAMED holds no validity date

FDA recalls

Not checked

No FDA submission to match recalls against

Documents

None linked in EUDAMED

A group certificate may exist

Trust

Unverified

Source EUDAMED, GUDID, synced 8 Nov 2026.

Regulatory status

as of registry sync 8 Nov 2026

RegionAuthorizationNumberDateStatus
European UnionCE/IVDR EUDAMED Number008407331ALETHIACLC011RE Basic UDI-DI 00840733102226UDI-DIDate15 Sep 2026RegisteredStatusActive
United StatesGUDID listing GUDID Number00840733102226 UDI-DI Date8 Jan 2019ListedStatusListed GUDID: in commercial distribution

Official records

From the FDA record

Device description
The Alethia Pertussis DNA Amplification Assay, performed on the Alethia Reader, is a qualitative in vitro diagnostic test for the direct detection of Bordetella pertussis in human nasopharyngeal swab samples taken from patients suspected of having respiratory tract infection attributable to Bordetella pertussis. The Alethia Pertussis assay utilizes loop-mediated isothermal DNA amplification (LAMP) technology to detect B. pertussis by targeting the IS481 insertional element of the B. pertussis genome. The IS481 insertional element can also be found in B. holmesii and some B. bronchiseptica strains. Respiratory infections with B. pertussis, B. holmesii or B. bronchiseptica may yield positive test results in IS481 assays. B. holmesii infection may cause clinical illness similar to B. pertussis, and mixed outbreaks involving both B. pertussis and B. holmesii infection have been reported. Additional testing should be performed if necessary to differentiate B. holmesii and B. pertussis. B. bronchiseptica is a rare cause of infection in humans. When clinical factors suggest that B. pertussis may not be the cause of respiratory infection, other clinically appropriate investigation(s) should be carried out in accordance with published guidelines. Negative results for the Alethia Pertussis DNA Amplification Assay do not preclude Bordetella pertussis infection and positive results do not rule out co-infection with other respiratory pathogens. Results from the Alethia Pertussis assay should be used in conjunction with information obtained during the patient’s clinical evaluation as an aid in diagnosis of B. pertussis infection and should not be used as the sole basis for treatment or other patient management decisions. Alethia Pertussis is intended for use in hospital, reference or state laboratory settings. The device is not intended for point-of-care use.
MRI safety
Labeling does not contain MRI Safety Information
Natural rubber latex
No latex statement on the label
Sterility
Supplied non-sterile

From the GUDID record (AccessGUDID), as read on 8 Nov 2026, as the labeller entered it.

Across registries

2 registries list this device

  • EUDAMED Basic UDI-DI 008407331ALETHIACLC011RE registered 15 Sep 2026 Active
  • FDA GUDID UDI-DI 00840733102226 listed 8 Jan 2019 Listed

Timeline

2 dated events

  1. Listed FDA GUDID 00840733102226
  2. Registered EUDAMED 008407331ALETHIACLC011RE

Coverage

2 jurisdictions

United States of AmericaSwedenFinlandLatviaEstoniaDenmarkLithuaniaIrelandNetherlandsGermanyPolandFranceBelgiumLuxembourgCzech RepublicSlovakiaAustriaHungaryRomaniaSloveniaBulgariaPortugalSpainItalyCroatiaGreeceMaltaCyprus
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered
  • European Union CE/IVDR Active
  • United States GUDID listing Listed

Specification

EUDAMED · GUDID

Trade name
alethia® Pertussis EUDAMED
Alethia™ Pertussis GUDID
Generic name
Bordetella pertussis nucleic acid IVD, kit, nucleic acid technique (NAT)
Model / Ref / Catalog
480750
Primary DI / UDI-DI
00840733102226
Basic UDI-DI
008407331ALETHIACLC011RE
Direct marketing DI
00840733102226
FDA product code
OZZ
EMDN code
W0105011607 Bordetella pertussis / parapertussis - na reagents
GMDN term
Bordetella pertussis nucleic acid IVD, kit, nucleic acid technique (NAT)
Device class
Class C EUDAMED
Class II GUDID
Regulation number
866.3980
EU registration type
Standard device
EU market of registration
Italy
GUDID distribution status
In Commercial Distribution

Truth per registry

2 sources · 1 field differs

FieldEUDAMEDGUDID
Device classEUDAMED
Class C
GUDID
Class II

Device class is stated on each registry's own scale: Class C in the EU (EUDAMED), Class II in the US (FDA GUDID). EU and US classes are different schemes, so this is not a disagreement.

Similar devices in this category

Other devices filed under OTHER BACTERIOLOGY - NA REAGENTS.

Other devices from Meridian Bioscience Inc.

See all devices from Meridian Bioscience Inc. →

Properties

  • Single use
  • Reagent
  • IVD kit
  • Professional testing
  • Prescription use
  • Convenience kit
  • Lot / batch number
  • Expiration date
Other properties (18, all answered No)